Document is current

Article History

Received: 14 July 2023

Accepted: 19 November 2023

First Online: 29 November 2023

Declarations

:

: The Japanese Ethical Guidelines for Medical and Biological Research Involving Human Subjects are not applied to clinical studies that use only anonymized data. The data used in this study were anonymized by the MDV. Therefore, informed consent was waived.

: Author Yasutaka Ihara, Miho Otani, Ryota Kawai, and Shingo Takatori declare they have no financial interests. Kenji Sawa received lecture fees in the past 36 months from Eli Lilly Japan, AstraZeneca, Ono Pharmaceutical, Nippon Kayaku, Chugai Pharmaceutical, Taiho Pharmaceutical, Nippon Boehringer Ingelheim, and Kyowa Kirin. Takumi Imai received lecture fees in the past 36 months from JCR Pharmaceuticals and Kyowa Kirin. TK is an employee of Daiichi Sankyo, which owns the patent for and manufactures one of the study drugs (olmesartan). Tetsuya Kimura was involved only in the study design and discussion of the results and played no role in data processing or conducting the analyses. Ayumi Shintani received lecture fees in the past 36 months from AbbVie, AstraZeneca plc, Asahi Kasei Corporation, Astellas Pharma, Bayer Yakuhin, Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Janssen Pharmaceutical, Kissei Pharmaceutical, Kyowa Kirin, Mallinckrodt Pharmaceuticals, Maruho, Merck Biopharma, Mitsubishi Tanabe Pharma Corporation, Nipro Corporation, Nippon Shinyaku, Novo Nordisk Pharma, Ono Pharmaceutical, Pfizer, Shionogi Pharma, Taisho Pharmaceutical, Takeda Pharmaceutical Company Limited, and Torii Pharmaceutical.